Keywords
Corticosteroids
Adolescent
How to Cite
Abstract
Introduction: Cushing’s Syndrome (CS) is an endocrinological disorder characterized by elevated and sustained cortisol levels. In childhood and adolescence, it is the most common cause is corticosteroid prolonged administration.
Objectives: to describe the case of an adolescent with exogenous CS; analyze the difficulties in its initial diagnosis; and reflect on the rational prescription of glucocorticoids.
Clinical case: 11-year-old male with a history of alopecia areata and treatment with prednisone 30 mg/day for 5 months. Weight gain of 15 kg, accompanied by mood swings, occurred. One week prior to consultation, the patient presented with polyuria, polydipsia, and polyphagia accompanied by abdominal pain. Examination revealed features characteristic of CS. The corticosteroids were gradually tapered, with favorable outcomes.
Discussion: the development of exogenous CS is related to prolonged administration of corticosteroids, which leads to alterations in the hypothalamic-pituitary-adrenal (HPA) axis, with manifestations such as central obesity, moon-shaped facial features, high blood pressure, hyperglycemia, and osteoporosis. Early diagnosis is essential to minimize this risk, as well as the implementation of strategies for gradual and controlled of the corticosteroid dose, allowing for functional recovery of the HPA axis.
References
Rodríguez F, Ibáñez L. Hiperfunción e hipofunción suprarrenal. En: Argente J. Tratado de endocrinología pediátrica y de la adolescencia. 2 ed. Barcelona: Doyma, 2000:1063-88.
Lodish M, Keil M, Stratakis C. Cushing’s syndrome in Pediatrics: an update. Endocrinol Metab Clin North Am 2018; 47(2):451-62. doi: 10.1016/j.ecl.2018.02.008.
Tabarin A, Assié G, Barat P, Bonnet F, Bonneville J, Borson F, et al. Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing’s syndrome. Ann Endocrinol (Paris) 2022; 83(2):119-41. doi: 10.1016/j.ando.2022.02.001.
Rice J, White A, Scarpati L, Wan G, Nelson W. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther 2017; 39(11):2216-29. doi: 10.1016/j.clinthera.2017.09.011
Aguirre M, Gutiérrez S, Quian J, Ramírez M, González V. Síndrome de Cushing secundario a interacción medicamentosa ritonavir/fluticasona. Arch Pediatr Urug 2012; 83(1):21-5. Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S1688-12492012000100005. (Consulta: 3 noviembre 2024).
Stambough K, Merritt D. Historia clínica y exploración física ginecológica. En: Kliegman R, St. Geme III J, Blum N, Shah S, Tasker R, Wilson K. Nelson tratado de pediatría. 21 ed. Barcelona: Elsevier, 2020:2842-3.
Hipercortisolismo. Sospecha de síndrome de Cushing. En: Guerrero J, González I. Manual de diagnóstico y terapéutica en endocrinología Pediátrica. Madrid: Ergon, 2020:678-82.
Rubio M, Colón A, Da Freitas L, Sáenz A, Ferreiro M. Síndrome de Cushing exógeno secundario al uso de clobetasol en el área del pañal. Presentación de un caso. Dermatol Venez 2015; 53(1):26-8.
Gutiérrez J. Efectos adversos de la terapia con glucocorticoides. Iatreia 2021; 34(2):137-50. doi: 10.17533/udea.iatreia.96.
Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster C. Long-term side effects of glucocorticoids. Expert Opin Drug Saf 2016; 15(4):457-65. doi: 10.1517/14740338.2016.1140743.
Agencia Española de Medicamentos y Productos Sanitarios. Centro de Información online de medicamentos de la AEMPS-CIMA. Disponible en: https://cima.aemps.es/cima/publico/home.html. (Consulta: 3 noviembre 2024).
Asociación Española de Pediatría. Comité de Medicamentos. Prednisona. Disponible en: https://www.aeped.es/comite-medicamentos/pediamecum/prednisona. (Consulta: 3 noviembre 2024).
Rapid Critical Care Consult. Potencias biológicas relativas de corticoides. Disponible en: www.rccc.eu/ppc/calculadoras/corticoides.htm. (Consulta: 3 noviembre 2024).
Fardet L, Fève B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs 2014; 74(15):1731-45. doi: 10.1007/s40265-014-0282-9.
Hardy R, Zhou H, Seibel M, Cooper M. Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr Rev 2018; 39(5):519-48. doi: 10.1210/er.2018-00097.
Tóth M, Grossman A. Glucocorticoid-induced osteoporosis: lessons from Cushing’s syndrome. Clin Endocrinol (Oxf) 2013; 79(1):1-11. doi: 10.1111/cen.12189.
Edwards I, Aronson J. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356(9237):1255-9. doi: 10.1016/S0140-6736(00)02799-9.
Joseph R, Hunter A, Ray D, Dixon W. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum 2016; 46(1):133-41. doi: 10.1016/j.semarthrit.2016.03.001.
Pombo M, Audí L, Bueno M, Calzada R, Cassorla F, Diéguez C, et al. Tratado de endocrinología pediátrica. 4 ed. Columbus, OH: McGraw-Hill Education, 2009.
Chabre O, Goichot B, Zenaty D, Bertherat J. Group 1. Epidemiology of primary and secondary adrenal insufficiency: Prevalence and incidence, acute adrenal insufficiency, long-term morbidity and mortality. Ann Endocrinol (Paris) 2017; 78(6):490-4. doi: 10.1016/j.ando.2017.10.010.
Organización Mundial de la Salud. Consejo Ejecutivo, 118. Uso racional de los medicamentos: progresos realizados en la aplicación de la estrategia farmacéutica de la OMS: informe de la Secretaría. Ginebra: OMS, 2006. Disponible en: https://apps.who.int/gb/ebwha/pdf_files/eb118/b118_6-sp.pdf. (Consulta: 3 noviembre 2024).
Sociedad Argentina de Pediatría. Comité Nacional de Endocrinología. Consideraciones para una corticoterapia segura. Arch Argent Pediatr 2018; 116(Supl 3):S71-6.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Miguel Ángel González, Alejandra Vomero, Martin Notejane, Patricia Purtscher, Federico Garafoni, Noelia Speranza, Loreley García